文献速递儿科与产科急症重症综合管理与镇静镇痛

儿童急性淋巴细胞白血病或淋巴瘤患者的COVID-19

COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma.
PubMed 文献 · JAMA Netw Open · 2024-02-05
一句话结论儿童ALL/LLy患者COVID-19重症少见(6%),但87%出现化疗中断,重症与化疗中断在奥密克戎前变异株期更长。

该回顾性病例系列纳入圣犹大儿童研究医院及其附属机构2020年3月30日至2022年6月20日期间按Total XVII方案(NCT03117751)治疗的新诊断ALL/LLy患儿,年龄1至18岁,共308例,其中110例(36%)发生COVID-19,中位年龄8.2岁(IQR 5.3-14.5),68例(62%)为男性,101例(92%)处于化疗继续/维持阶段。重症7例(6%),与年龄较大、ALL/LLy诊断时白细胞计数较高、COVID-19诊断时绝对淋巴细胞计数较低、胸部影像异常及SARS-CoV-2再感染相关;无儿童多系统炎症综合征或死亡,肺栓塞和脑静脉窦血栓各1例。再感染11例(10%),与年龄较大及接受标准或高危相比低危ALL/LLy治疗相关;96例(87%)化疗中断,重症、再感染及奥密克戎前变异株期诊断者中断更长。作者认为需长期研究确定该人群COVID-19结局。

要点

  • 308例ALL/LLy患儿中110例(36%)发生COVID-19,101例(92%)处于化疗继续/维持阶段,重症仅7例(6%)。
  • 重症COVID-19与年龄较大、ALL/LLy诊断时白细胞计数较高、COVID-19诊断时绝对淋巴细胞计数较低、胸部影像异常及SARS-CoV-2再感染相关。
  • 无儿童多系统炎症综合征或死亡;罕见严重血栓事件包括肺栓塞和脑静脉窦血栓各1例。
  • SARS-CoV-2再感染11例(10%),与年龄较大及接受标准或高危相比低危ALL/LLy治疗相关。
  • 化疗中断96例(87%),重症、再感染及奥密克戎前变异株期(2021年12月27日前)诊断者中断更长。

适用人群与场景

  • 圣犹大儿童研究医院及其附属机构2020年3月30日至2022年6月20日期间按Total XVII方案(NCT03117751)治疗的新诊断ALL/LLy患儿,年龄1至18岁,正在接受方案化疗。
  • 所有患者至少每周筛查SARS-CoV-2,并在症状出现和/或已知暴露后筛查。

红旗征与不能漏的情况

  • 重症COVID-19(7例,6%)与年龄较大、ALL/LLy诊断时白细胞计数较高、COVID-19诊断时绝对淋巴细胞计数较低、胸部影像异常及SARS-CoV-2再感染相关。
  • 罕见但严重的血栓事件包括肺栓塞和脑静脉窦血栓(各1例)。

研究设计与关键结果

  • 回顾性病例系列,308例ALL/LLy患儿中110例(36%)发生COVID-19,中位年龄8.2岁(IQR 5.3-14.5),68例(62%)为男性,101例(92%)处于化疗继续/维持阶段。
  • 重症COVID-19 7例(6%),与年龄较大、ALL/LLy诊断时白细胞计数较高、COVID-19诊断时绝对淋巴细胞计数较低、胸部影像异常及SARS-CoV-2再感染相关。
  • 无儿童多系统炎症综合征或死亡;肺栓塞和脑静脉窦血栓各1例。
  • SARS-CoV-2再感染11例(10%),与年龄较大及接受标准或高危相比低危ALL/LLy治疗相关。
  • 化疗中断96例(87%),重症、SARS-CoV-2再感染和/或奥密克戎前变异株期(2021年12月27日前)诊断者中断更长。

证据类型、等级与局限

  • 证据类型:回顾性病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在该ALL/LLy患儿病例系列中,重症COVID-19罕见,但大多数患者化疗给药受到影响。
  • 作者认为,需长期研究确定该人群COVID-19的结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 in pediatric patients with acute lymphoblastic leukemia or lymphoma (ALL/LLy) has not been described in detail and may affect chemotherapy administration and long-term outcomes.

OBJECTIVE: To describe the clinical presentation of COVID-19 and chemotherapy modifications in pediatric patients with ALL/LLy.

DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective case series of patients at St Jude Children's Research Hospital and its affiliate sites with newly diagnosed ALL/LLy who were treated on the Total XVII protocol (NCT03117751) between March 30, 2020, and June 20, 2022. Participants included patients aged 1 to 18 years who were receiving protocol chemotherapy. Acute symptoms and chemotherapy modifications were evaluated for 60 days after the COVID-19 diagnosis, and viral clearance, adverse events, and second SARS-CoV-2 infections were followed up during the 27-month study period.

EXPOSURES: SARS-CoV-2; all patients were screened at least weekly and at symptom onset and/or after known exposure to SARS-CoV-2.

MAIN OUTCOMES AND MEASURES: Description of the spectrum of COVID-19 illness and chemotherapy modifications.

RESULTS: Of 308 pediatric patients, 110 (36%) developed COVID-19 at a median age of 8.2 (IQR, 5.3-14.5) years. Sixty-eight patients (62%) were male. Most patients were in the continuation/maintenance phase of chemotherapy (101 [92%]). Severe disease was rare (7 [6%]) but was associated with older age, higher white blood cell counts at ALL/LLy diagnosis, lower absolute lymphocyte counts at COVID-19 diagnosis, abnormal chest imaging findings, and SARS-CoV-2 reinfection. Rare but serious thrombotic events included pulmonary embolism and cerebral venous sinus thrombosis (n = 1 for each). No multisystem inflammatory syndrome in children or death was seen. SARS-CoV-2 reinfection occurred in 11 patients (10%) and was associated with older age and with receiving standard or high-risk vs low-risk ALL/LLy therapy. Chemotherapy interruptions occurred in 96 patients (87%) and were longer for patients with severe disease, SARS-CoV-2 reinfection, and/or a COVID-19 diagnosis during the pre-Omicron variant period vs the post-Omicron period (after December 27, 2021).

CONCLUSIONS AND RELEVANCE: In this case series of COVID-19 in pediatric patients with ALL/LLy, severe COVID-19 was rare, but chemotherapy administration was affected in most patients. Long-term studies are needed to establish the outcomes of COVID-19 in this population.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hashmi SK, Bodea J, Patni T, et al. COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma. JAMA Netw Open. 2024. PMID: 38363571. doi:10.1001/jamanetworkopen.2023.55727

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。